| Nov 21 |
Korro to Participate in Upcoming Investor Conferences
|
| Nov 21 |
Korro gets Australian HREC approval to initiate phase 1/2a study for antitrypsin deficiency
|
| Nov 21 |
Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency
|
| Nov 14 |
Korro to Present at the Jefferies London Healthcare Conference
|
| Nov 13 |
Korro Bio GAAP EPS of -$2.26
|
| Nov 12 |
Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates
|
| Nov 4 |
Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board
|
| Oct 21 |
Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space.
|
| Oct 16 |
Wave Life Sciences Just Edited RNA. Why Its Key Rival, Korro Bio, Skyrocketed.
|
| Sep 30 |
Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society
|
